Replies to post #26362 on ViaDerma Inc (VDRM)

[chico2663]

ViaDerma, Inc. Set to Begin Sales of its FDA Registered Topical Antibiotic in September with Initial Orders from Japan
Viaderma, Inc. announces Galaxy Solutions, Inc. as new sales representative for select Asia Pacific markets
LOS ANGELES, CA--(Marketwired - August 18, 2017) - ViaDerma, Inc. (OTC PINK: VDRM), a specialty pharmaceutical company devoted to bringing new products to market, announced today that it has appointed Galaxy Solutions, Inc. as its sales representative for its first aid topical antibiotic which will be sold under the brand name Vitastem in select markets of Asia Pacific, starting in Japan. The agreement includes sales and marketing responsibilities of the Vitastem brand and possible other brands that will be developed for specific market segments. Galaxy Solutions, Inc. will work to sell directly to larger customers and to distributors and will be the primary provider of service and support in the covered markets.
"With Galaxy Solutions as our sales representative, we will immediately have access to the professional segment of our target markets," said Dr. Chris Otiko, CEO of Viaderma, Inc. "Our goal is to continuously increase our revenues and improve our customers' experience in every aspect. Expanding our network of sales and support personnel and being in close proximity to where our customers are is a key initiative towards achieving that. With competitive pricing for retail sales through doctor's offices in Japan, the Company is conservatively estimating 2018 sales in Japan alone at approximately $12 million US dollars."
"Over the last 7 years Galaxy Solutions has established itself as a premier supplier of epidermal healing solutions, anti-aging solutions and beautification solutions. The relationship with Galaxy Solutions, Inc. will allow us to introduce our products to several markets, initially in Japan and then throughout Asia Pacific, immediately," said Otiko.
"Product testing has already begun and we are expecting to place an initial order in the next 30-45 days. I expect sales to be at around 10,000 units per month in the first 4-6 months and we hope to double that to 20,000 units per month in 2018 in Japan alone. The current testing is being done on sores resulting form side effects of cancer treatments and this will be our initial market, next we expect to introduce a product for acne," said Don Heath, President and CEO of Galaxy Solutions, Inc.